Foghorn Therapeutics (FHTX) Short-term Investments (2019 - 2026)
Foghorn Therapeutics (FHTX) posted quarterly Short-term Investments of $1.2 million for Q1 2026, little changed quarter-over-quarter from $1.2 million in Q4 2025.
Analysis
Foghorn Therapeutics (FHTX) Short-term Investments (2019 - 2026) Analysis & Trends
Foghorn Therapeutics' Short-term Investments history runs 5 years deep, the most recent figure standing at $1.2 million for Q1 2026.
- In Q1 2026, Short-term Investments changed N/A year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $1.2 million (changed N/A YoY), while the FY2025 annual figure was $1.2 million, changed N/A from the prior year.
- Short-term Investments for Q1 2026 stood at $1.2 million, roughly flat from $1.2 million in the prior quarter.
- The five-year high for Short-term Investments was $1.2 million in Q2 2025, with the low at $25000.0 in Q3 2022.
- The 3-year median for Short-term Investments is $1.2 million (2025), against an average of $1.0 million.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn |
| 10 | Foghorn Therapeutics | 346.08 Mn | 278.00 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 1.25 Mn |
| Dec 31, 2025 | 1.25 Mn |
| Sep 30, 2025 | 1.25 Mn |
| Jun 30, 2025 | 1.25 Mn |
| Sep 30, 2022 | 25,000.00 |
| Sep 30, 2020 | 541,000.00 |
| Dec 31, 2019 | 541,000.00 |